- Home
- SRTS vs MNOV Comparison
SRTS vs MNOV Comparison
Compare SRTS & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRTS | MNOV |
|---|---|---|
| Founded | 2010 | 2000 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.3M | 72.7M |
| IPO Year | 2016 | 2004 |
Fundamental Metrics
Financial Performance| Metric | SRTS | MNOV |
|---|---|---|
| Price | $3.83 | $1.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $6.67 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 109.6K | 66.8K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1266.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,807,000.00 | $2,360,807.00 |
| Revenue This Year | $31.80 | N/A |
| Revenue Next Year | $32.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 71.31 | ★ 194.15 |
| 52 Week Low | $3.03 | $1.13 |
| 52 Week High | $5.92 | $1.96 |
Technical Indicators
Market Signals| Indicator | SRTS | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 30.57 | 47.54 |
| Support Level | $3.73 | $1.47 |
| Resistance Level | $4.99 | $1.69 |
| Average True Range (ATR) | 0.27 | 0.09 |
| MACD | -0.17 | -0.02 |
| Stochastic Oscillator | 16.26 | 26.97 |
Price Performance
Historical ComparisonAbout SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.